105 related articles for article (PubMed ID: 38728549)
1. A β-Carboline Derivate PAD4 Inhibitor Reshapes Neutrophil Phenotype and Improves the Tumor Immune Microenvironment against Triple-Negative Breast Cancer.
Zhu D; Lu Y; Yan Z; Deng Q; Hu B; Wang Y; Wang W; Wang Y; Wang Y
J Med Chem; 2024 May; 67(10):7973-7994. PubMed ID: 38728549
[TBL] [Abstract][Full Text] [Related]
2. Highly-tumor-targeted PAD4 inhibitors with PBA modification inhibit tumors in vivo by specifically inhibiting the PAD4-H3cit-NETs pathway in neutrophils.
Zhu D; Lu Y; Hu B; Pang Y; Liu B; Zhang M; Wang W; Wang Y
Eur J Med Chem; 2023 Oct; 258():115619. PubMed ID: 37421890
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
4. Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer.
Deng Y; Hu JC; He SH; Lou B; Ding TB; Yang JT; Mo MG; Ye DY; Zhou L; Jiang XC; Yu K; Dong JB
Acta Pharmacol Sin; 2021 Jan; 42(1):149-159. PubMed ID: 32451413
[TBL] [Abstract][Full Text] [Related]
5. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
[TBL] [Abstract][Full Text] [Related]
7. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
8. Endogenous PAD4 in Breast Cancer Cells Mediates Cancer Extracellular Chromatin Network Formation and Promotes Lung Metastasis.
Shi L; Yao H; Liu Z; Xu M; Tsung A; Wang Y
Mol Cancer Res; 2020 May; 18(5):735-747. PubMed ID: 32193354
[TBL] [Abstract][Full Text] [Related]
9. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
[TBL] [Abstract][Full Text] [Related]
10. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of novel tetrahydro-β-carboline derivatives as antitumor growth and metastasis agents through inhibiting the transforming growth factor-β signaling pathway.
Zheng C; Fang Y; Tong W; Li G; Wu H; Zhou W; Lin Q; Yang F; Yang Z; Wang P; Peng Y; Pang X; Yi Z; Luo J; Liu M; Chen Y
J Med Chem; 2014 Feb; 57(3):600-12. PubMed ID: 24417479
[TBL] [Abstract][Full Text] [Related]
12. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
13. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.
Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK
Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253
[TBL] [Abstract][Full Text] [Related]
14. Silencing of Pyruvate Kinase M2
Huang S; Zhu W; Zhang F; Chen G; Kou X; Yang X; Ouyang G; Shen J
ACS Appl Mater Interfaces; 2021 Dec; 13(48):56972-56987. PubMed ID: 34797638
[TBL] [Abstract][Full Text] [Related]
15. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1.
Singh M; Ramos I; Asafu-Adjei D; Quispe-Tintaya W; Chandra D; Jahangir A; Zang X; Aggarwal BB; Gravekamp C
Cancer Med; 2013 Aug; 2(4):571-82. PubMed ID: 24156030
[TBL] [Abstract][Full Text] [Related]
16. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
[TBL] [Abstract][Full Text] [Related]
18. Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model.
Zhang Q; Le K; Xu M; Zhou J; Xiao Y; Yang W; Jiang Y; Xi Z; Huang T
Int Immunopharmacol; 2019 Nov; 76():105864. PubMed ID: 31480004
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
20. Exploring Marine-Derived Ascochlorins as Novel Human Dihydroorotate Dehydrogenase Inhibitors for Treatment of Triple-Negative Breast Cancer.
Luo X; Cai G; Guo Y; Gao C; Huang W; Zhang Z; Lu H; Liu K; Chen J; Xiong X; Lei J; Zhou X; Wang J; Liu Y
J Med Chem; 2021 Sep; 64(18):13918-13932. PubMed ID: 34516133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]